HUTCHMED Initiates P-III Trial of HMPL-760 + R-GemOx for R/R Diffuse Large B-Cell Lymphoma in China

Why It Matters

If successful, the regimen could become a new standard for transplant‑ineligible R/R DLBCL, addressing an unmet need in a large Chinese patient population. It also strengthens HUTCHMED’s oncology pipeline and may attract further investment.

Key Takeaways

• Phase III trial starts with 240 Chinese DLBCL patients.
• HMPL‑760 combined with R‑GemOx versus placebo.
• Phase II showed higher ORR, CRR, PFS, OS.
• Targets patients ineligible for transplantation.
• First dose administered March 20, 2026.

Pulse Analysis

Diffuse large B‑cell lymphoma (DLBCL) remains the most common aggressive non‑Hodgkin lymphoma worldwide, and China accounts for a substantial share of new cases each year. While first‑line immunochemotherapy cures many patients, roughly 30‑40 % relapse or become refractory, and a large subset cannot undergo high‑dose therapy with autologous stem‑cell transplantation due to age, comorbidities, or donor availability. This transplant‑ineligible cohort faces limited options, relying on salvage regimens that often deliver modest response rates and short survival. Consequently, the Chinese oncology community is actively seeking novel combinations that can improve outcomes without excessive toxicity.

HMPL‑760 is a selective inhibitor of Bruton’s tyrosine kinase (BTK), a pathway integral to B‑cell receptor signaling and lymphoma survival. When paired with the R‑GemOx backbone—rituximab, gemcitabine, and oxaliplatin—the drug aims to deepen remissions by simultaneously targeting surface antigens and intracellular survival signals. A preceding Phase II study reported notable gains in overall response rate, complete response rate, progression‑free survival, and overall survival, while maintaining a manageable safety profile. These data prompted HUTCHMED to advance the combination into a pivotal Phase III trial, enrolling about 240 patients to compare HMPL‑760 + R‑GemOx against placebo + R‑GemOx.

The outcome of this trial could reshape the therapeutic algorithm for relapsed/refractory DLBCL in China, offering a chemotherapy‑free targeted option for patients who cannot tolerate transplant. A positive readout would also bolster HUTCHMED’s position in the competitive BTK‑inhibitor market, potentially unlocking partnerships or accelerated regulatory pathways. Moreover, success may encourage broader adoption of BTK inhibition in other B‑cell malignancies, reinforcing the trend toward precision‑medicine combinations. Investors and clinicians alike will be watching the interim safety data closely, as it may set the stage for global expansion of the regimen.